Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 7/20 | 0.49 |
| ▸ | S1PR1 | P21453 | 2/20 | 0.49 |
| ▸ | S1PR4 | O95977 | 3/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | RECQL | P46063 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | ATM | Q13315 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | MBTPS1 | Q14703 | 1/20 | 0.42 |
| ▸ | TYR | P14679 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL3336871 | 0.99 | MAPT (0.48) | MAPTS1PR1S1PR4ALDH1A1RECQL | |
| SCHEMBL3336890 | 0.89 | MAPT (0.39) | MAPTS1PR1S1PR4 | |
| Hydrochloric Acid SCHEMBL3334883 | 0.88 | MAPT (0.39) | MAPTS1PR1S1PR4 | |
| SCHEMBL3335362 | 0.88 | ROCK2 (0.40) | MAPTS1PR1 | |
| SCHEMBL3338292 | 0.88 | TACR1 (0.41) | MAPTS1PR1S1PR4MEN1KMT2A | |
| Hydrochloric Acid SCHEMBL3625843 | 0.87 | ROCK2 (0.39) | MAPTS1PR1 | |
| Hydrochloric Acid SCHEMBL3335270 | 0.87 | ROCK2 (0.39) | MAPTS1PR1 | |
| Hydrochloric Acid SCHEMBL3339470 | 0.87 | TACR1 (0.40) | MAPTS1PR1S1PR4MEN1KMT2A | |
| SCHEMBL27786110 | 0.87 | MAPT (0.47) | MAPTS1PR1S1PR4ALDH1A1RECQL | |
| SCHEMBL27782059 | 0.86 | SMN1; SMN2 (0.42) | MAPTS1PR1ALDH1A1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2202227-B1 | NOVEL HISTIDINE DERIVATIVE | NIPPON ZOKI PHARMACEUTICAL CO (JP) | 2013-11-20 | — | — | EP | disclosed |
| US-8324261-B2 | Histidine derivatives | NIPPON ZOKI PHARMACEUTICAL CO., LTD. (JP) | 2012-12-04 | — | — | US | disclosed |
| EP-2202227-A1 | NOVEL HISTIDINE DERIVATIVE | Nippon Zoki Pharmaceutical Co., Ltd. (JP) | 2010-06-30 | — | — | EP | disclosed |
| US-20100152459-A1 | NOVEL HISTIDINE DERIVATIVES | NIPPON ZOKI PHARMACEUTICAL CO., LTD. (JP) | 2010-06-17 | — | — | US | disclosed |
| US-5250517-A | Hypotensive and cardiotonic agents; cardiac insufficiency | HOFFMANN-LA ROCHE INC. (US) | 1993-10-05 | — | — | US | disclosed |
| EP-0310918-A2 | Peptide-like amino-acid derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 1989-04-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100152459-A1 | NOVEL HISTIDINE DERIVATIVES | HRH4, HNMT, HRH3 | MAPT 3851/4885S1PR1 2270/4885S1PR4 2254/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.